Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Too Little, Too Late For GSK/Janssen's Sirukumab in RA?

Executive Summary

Full data for the Phase III SIRROUND-D study of GlaxoSmithKline PLC/Janssen Pharmaceuticals Inc.'s sirukumab show early and good separation over placebo in rheumatoid arthritis, but the third-placed anti-IL6 product will have to work hard to catch up with its more advanced rivals, Actemra (tocilizumab) and sarilumab.

Advertisement

Related Content

ACR 2016 Roundup: Remicade Copy Not So Similar; Mixed Sirukumab Results; Corbus’s Resunab Surge
GSK's Immunology Strategy Edges Closer To Delivering
Keeping Track: Ilaris Adds Three Rare Disease Claims; Sirukumab Submitted; Exondys 51's Surprising Approval

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register